Effects of a single terlipressin administration on cardiac function and perfusion in cirrhosis

European Journal of Gastroenterology and Hepatology

Volumn 22, Issue 9, 2010, Pages 1085-1092

  Krag, Aleksander ^a,b   Bendtsen, Flemming ^b   Mortensen, Christian ^a,b   Henriksen, Jens H ^a   Møller, Søren ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b HVIDOVRE HOSPITAL   (Denmark)

Author keywords

cardiac output; cirrhotic cardiomyopathy; heart; hepatorenal syndrome; portal hypertension; terlipressin

Indexed keywords

METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; PLACEBO; TERLIPRESSIN;

ADULT; ARTICLE; ASCITES; BOLUS INJECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE WALL; HEART MUSCLE; HEART OUTPUT; HEART PERFUSION; HEART STROKE VOLUME; HUMAN; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; MOTION; MYOCARDIAL PERFUSION IMAGING; PRIORITY JOURNAL; QT INTERVAL; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL; THICKNESS; TREATMENT DURATION;

AGED; ASCITES; BLOOD PRESSURE; CARDIAC OUTPUT; ELECTROCARDIOGRAPHY; FEMALE; HEART FUNCTION TESTS; HUMANS; LIVER CIRRHOSIS; LYPRESSIN; MALE; MIDDLE AGED; STROKE VOLUME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASOCONSTRICTOR AGENTS; VENTRICULAR FUNCTION, LEFT;

EID: 77955469970     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32833a4822     Document Type: Article

References (46)

1. Ioannou G, Doust J, Rockey DC. Terlipressin for acute esophageal variceal hemorrhage. Cochrane Database Syst Rev 2003; 1:CD002147.
2. Moreau R, Lebrec D. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond. Hepatology 2006; 43:385-394.
3. Salerno F, Gerbes A, Gines P, Wong F, Arroyo V. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Gut 2007; 56:1310-1318.
4. Morelli A, Ertmer C, Westphal M. Terlipressin in the treatment of septic shock: the earlier the better? Best Pract Res Clin Anaesthesiol 2008; 22:317-321.
5. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem Biophys Res Commun 1994; 203:72-79.
6. Walker BR, Childs ME, Adams EM. Direct cardiac effects of vasopressin: role of V1- and V2-vasopressinergic receptors. Am J Physiol 1988; 255:H261-H265.
7. Boyle WA III, Segel LD. Direct cardiac effects of vasopressin and their reversal by a vascular antagonist. Am J Physiol 1986; 251:H734-H741.
8. Ouattara A, Landi M, Le MY, Lecomte P, Leguen M, Boccara G, et al. Comparative cardiac effects of terlipressin, vasopressin, and norepinephrine on an isolated perfused rabbit heart. Anesthesiology 2005; 102:85-92.
9. Barrett LK, Singer M, Clapp LH. Vasopressin: mechanisms of action on the vasculature in health and in septic shock. Crit Care Med 2007; 35:33-40.
10. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000; 20:51-59.
11. Krag A, Borup T, Møller S, Bendtsen F. Efficacy and safety of terlipressin in cirrhotic patients with variceal bleeding or hepatorenal syndrome. Adv Ther 2008; 25:1105-1140.
12. Rosario R, Lalanne B, Lebre P, Lepesan D, Martelet JP, Dupont M, et al. Myocardial infarction after injection of terlipressin for digestive hemorrhage. Gastroenterol Clin Biol 1996; 20:712-713.
13. Lee MY, Chu CS, Lee KT, Lee HC, Su HM, Cheng KH, et al. Terlipressin-related acute myocardial infarction: a case report and literature review. Kaohsiung J Med Sci 2004; 20:604-608.
14. Freeman JG, Cobden I, Lishman AH, Record CO. Controlled trial of terlipressin ('Glypressin') versus vasopressin in the early treatment of oesophageal varices. Lancet 1982; 2:66-68.
15. Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine. Hepatology 1999; 30:870-875.
16. Guevara M, Gines P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27:35-41.
17. Tristani FE, Cohn JN. Systemic and renal hemodynamics in oliguric hepatic failure: effect of volume expansion. J Clin Invest 1967; 46:1894-1906.
18. Møller S, Bendtsen F, Henriksen JH. Effect of volume expansion on systemic hemodynamics and central and arterial blood volume in cirrhosis. Gastroenterology 1995; 109:1917-1925.
19. Ruiz-del-Arbol L, Urman J, Fernandez J, Gonzalez M, Navasa M, Monescillo A, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38:1210-1218.
20. Ruiz-del-Arbol L, Monescillo A, Arocena C, Valer P, Gines P, Moreira V, et al. Circulatory function and hepatorenal syndrome in cirrhosis. Hepatology 2005; 42:439-447.
21. Krag A, Bendtsen F, Henriksen JH, Møller S. Low cardiac output predicts development of hepatorenal syndrome and survival in patients with cirrhosis and ascites. Gut 2010; 59:105-110.
22. Sciagra R. The expanding role of left ventricular functional assessment using gated myocardial perfusion SPECT: the supporting actor is stealing the scene. Eur J Nucl Med Mol Imaging 2007; 34:1107-1122.
23. Abidov A, Germano G, Hachamovitch R, Berman DS. Gated SPECT in assessment of regional and global left ventricular function: major tool of modern nuclear imaging. J Nucl Cardiol 2006; 13:261-279.
24. Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, et al. EANM/ESC procedural guidelines for myocardial perfusion imaging in nuclear cardiology. Eur J Nucl Med Mol Imaging 2005; 32:855-897.
25. DuBois D, DuBois EF. A formula to estimate the approximate surface area if height and weight be known. Arch Intern Med 1916; 17:863-871.
26. Henriksen JH, Fuglsang S, Bendtsen F, Christensen E, Møller S. Dyssynchronous electrical and mechanical systole in patients with cirrhosis. J Hepatol 2002; 36:513-520.
27. Bazett H. An analyses of the time-relations of electrocardiograms. Heart 1920; 7:353-753.
28. Fredericia L. Die Systolendauer im Elektrokardiogramm bei normalen Menshenund bei Herzkranken. Acta Med Scandina 1920; 53:469-486.
29. Kelbaek H, Rabol A, Brynjolf I, Eriksen J, Bonnevie O, Godtfredsen J, et al. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. Clin Physiol 1987; 7:35-41.
30. Grose RD, Nolan J, Dillon JF, Errington M, Hannan WJ, Bouchier IA, Hayes PC. Exercise-induced left ventricular dysfunction in alcoholic and non-alcoholic cirrhosis. J Hepatol 1995; 22:326-332.
31. Torregrosa M, Aguade S, Dos L, Segura R, Gonzalez A, Evangelista A, et al. Cardiac alterations in cirrhosis: reversibility after liver transplantation. J Hepatol 2005; 42:68-74.
32. Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49:268-275.
33. Gould L, Shariff M, Zahir M, Di LM. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969; 48:860-868.
34. Regan TJ, Levinson GE, Oldewurtel HA, Frank MJ,Weisse AB, Moschos CB. Ventricular function in noncardiacs with alcoholic fatty liver: role of ethanol in the production of cardiomyopathy. J Clin Invest 1969; 48:397-407.
35. Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001; 93:7-13.
36. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001; 27:1416-1421.
37. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003; 31:2646-2650.
38. Koshimizu TA, Nasa Y, Tanoue A, Oikawa R, Kawahara Y, Kiyono Y, et al. V1a vasopressin receptors maintain normal blood pressure by regulating circulating blood volume and baroreflex sensitivity. Proc Natl Acad Sci U S A 2006; 103:7807-7812.
39. Zhang X, Abdel-Rahman AR, Wooles WR. Vasopressin receptors in the area postrema differentially modulate baroreceptor responses in rats. Eur J Pharmacol 1992; 222:81-91.
40. Hasser EM, Bishop VS, Hay M. Interactions between vasopressin and baroreflex control of the sympathetic nervous system. Clin Exp Pharmacol Physiol 1997; 24:102-108.
41. Zambruni A, Di MA, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol 2007; 18:77-82.
42. Henriksen JH, Gulberg V, Fuglsang S, Schifter S, Bendtsen F, Gerbes AL, Moller S. Q-T interval (QT(C)) in patients with cirrhosis: relation to vasoactive peptides and heart rate. Scand J Clin Lab Invest 2007; 67:643-653.
43. Ertmer C, Morelli A, Bone HG, Stubbe HD, Schepers R, Van AH, et al. Dobutamine reverses the vasopressin-associated impairment in cardiac index and systemic oxygen supply in ovine endotoxemia. Crit Care 2006; 10:R144.
44. Lange M, Morelli A, Ertmer C, Koehler G, Broking K, Hucklenbruch C, et al. Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 2007; 28:623-629.
45. Gerbes AL, Huber E, Gulberg V. Terlipressin for hepatorenal syndrome: continuous infusion as an alternative to i.v. bolus administration. Gastroenterology 2009; 137:1179-1181.
46. Angeli P, Fasolato S, Cavallin M, Maresio G, Callegaro A, Sticca A, et al. Terlipressin given as continuous intravenous infusion is the more suitable schedule for the treatment of type 1 hepatorenal syndrome (Hrs) in patients with cirrhosis: results of a controlled clinical study. Hepatology 2008; 48:LB3.